Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024)

Syndax Pharmaceuticals (SNDX) has 4 years of Non-Current Debt data on record, last reported at $331.6 million in Q4 2024.

  • For Q4 2024, Non-Current Debt changed N/A year-over-year to $331.6 million; the TTM value through Dec 2024 reached $331.6 million, changed N/A, while the annual FY2024 figure was $331.6 million, N/A changed from the prior year.
  • Non-Current Debt reached $331.6 million in Q4 2024 per SNDX's latest filing, up from $13.0 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $331.6 million in Q4 2024 and bottomed at $11.0 million in Q3 2021.
  • Average Non-Current Debt over 4 years is $45.3 million, with a median of $17.8 million recorded in 2020.
  • The widest YoY moves for Non-Current Debt: up 11.56% in 2021, down 45.07% in 2021.
  • A 4-year view of Non-Current Debt shows it stood at $17.8 million in 2020, then rose by 11.56% to $19.9 million in 2021, then tumbled by 34.69% to $13.0 million in 2022, then skyrocketed by 2451.68% to $331.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $331.6 million in Q4 2024, $13.0 million in Q2 2022, and $16.5 million in Q1 2022.